Loading stock data…
$13.95-2.60 (-15.71%)
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Syndax Pharmaceuticals, Inc. in the Healthcare sector is trading at $13.95 with a market capitalization of $1.5B. Wall Street consensus targets $37.27 (11 analysts), implying a +167.2% move over the next 12 months. The stock is currently near its 52-week low of $12.99, remaining 32.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $72.79M↑ | $64.86M↓ | $68.73M↑ | $45.87M↑ | $37.96M |
| Gross Profit | $69.58M↑ | $62.23M↓ | $66.02M↑ | $43.77M↑ | $36.68M |
| Operating Income | -$39.99M↓ | -$34.20M↑ | -$62.55M↓ | -$57.43M↑ | -$69.35M |
| Net Income | -$49.36M↓ | -$42.67M↑ | -$68.01M↓ | -$60.72M↑ | -$71.85M |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R ac...